Treatment with systemic immunostimulatory agents (including, but not limited to, interferon-alpha or interleukin- [aldesleukin]) within  weeks prior to cycle , day .
Treatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-) within  weeks prior to cycle , day 
Treatment with systemic immunostimulatory medications (including, but not limited to interferon [IFN]-alpha or interleukin [IL]- within  days prior to randomization
Prior treatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-) is allowed, provided the following is met: minimum of  weeks prior to cycle , day 
Treatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-) within  weeks prior to cycle , day 
Treatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-) within  weeks prior to cycle , day 
Treatment with systemic immunostimulatory agents (including but not limited to interferon [IFN]-alpha or interleukin [IL]-) within  weeks or five half-lives of the drug (whichever is shorter) prior to cycle , day 
MEDICATION-RELATED: Treatment with systemic immunostimulatory agents (including but not limited to interferon [IFN]-alpha or interleukin [IL]-) within  weeks or five half-lives of the drug (whichever is shorter) prior to cycle , day .
Treatment with systemic immunostimulatory agents (including but not limited to interferon [IFN]-alpha or interleukin [IL]-) within  weeks or five half-lives of the drug (whichever is shorter) prior to start of study treatment.
Treatment with systemic immunostimulatory agents (including but not limited to interferon [IFN]-a or interleukin [IL]-) within  weeks or five half-lives of the drug (whichever is shorter) prior to cycle , day 
Treatment with systemic immunostimulatory agents (including but not limited to interferon [IFN]-a or interleukin [IL]-) within  weeks or five half-lives of the drug (whichever is shorter) prior to study treatment
(Atezolizumab-related exclusion) Treatment with systemic immunostimulatory agents (including but not limited to interferon [IFN]-(alpha) or interleukin [IL]-) within  weeks or five half-lives of the drug (whichever is shorter) prior to cycle , day 
Treatment with systemic immunostimulatory agents (including but not limited to IFNs, interleukin [IL]-) within  weeks or five half-lives of the drug, whichever is shorter, prior to cycle  day 
Treatment with systemic immuno-stimulatory agents (including but not limited to interferon [IFN] or interleukin [IL]-) within  weeks or five half-lives of the drug (whichever is shorter) prior to cycle , day 
Treatment with systemic immunostimulatory agents (including but not limited to interferon [IFN]-alpha or interleukin [IL]-) within  weeks or five half-lives of the drug (whichever is shorter) prior to cycle , day 
Patients who have received treatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-) within  weeks before initiation of study treatment
Treatment with systemic immunostimulatory agents (including but not limited to interferon [IFN] or interleukin [IL]-) within  weeks or five half-lives of the drug (whichever is shorter) prior to cycle , day .
Treatment with systemic immunostimulatory agents (including, but not limited to, interferon-alpha or interleukin-) within  weeks or five half-lives of the drug (whichever is shorter) prior to registration
Treatment with systemic immunostimulatory agents (including but not limited to interferon [IFN]-alpha or interleukin [IL]-) within  weeks or five half-lives of the drug (whichever is shorter) prior to cycle , day 
Treatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-) within  weeks prior to cycle , day 
Treatment with systemic immunostimulatory agents (including but not limited to IFN-alpha, IL-) within  weeks or five half-lives of the drug (whichever is shorter) prior to cycle , day 
Hypersensitivity to interferon-alpha (IFN-alpha)
Treatment with systemic immunostimulatory agents (including but not limited to interferon, interleukin-) within  weeks or  half-lives of the drug, whichever is shorter, prior to Cycle , Day 
Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin  [IL-]) within  weeks or five half-lives of the drug (whichever is longer) prior to initiation of study treatment
Treatment with systemic immunostimulatory agents (including but not limited to interferon [IFN]
Treatment with systemic immunostimulatory agents (including but not limited to interferon [IFN]-alpha or interleukin [IL]-) within  weeks or five half-lives of the drug (whichever is shorter) prior to cycle , day 
Treatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-) within  weeks prior to cycle , day 
FOLLOWING ARE medication-related exclusion criteria: \r\n*Treatment with systemic immunostimulatory agents (including but not limited to interferon-a [IFN-a], interleukin [IL]-) within  weeks or five half-lives of the drug (whichever is shorter) prior to the start of chemoradiation; treatment with investigational agent within  weeks prior to cycle , day  (or within five half lives of the investigational product, whichever is longer)
Treatment with systemic immunostimulatory agents (including but not limited to interferon [IFN]-alpha or interleukin [IL]-) within  weeks or five half-lives of the drug (whichever is shorter) prior to cycle , day 
Only prior cytokine based treatment for metastatic RCC [eg, interferon-alpha (IFN-alpha) or interleukin  (IL-)] as prior therapy is allowed
Treatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-) within  weeks prior to cycle , day 
Treatment with systemic immunostimulatory agents (including but not limited to IFN , IL-) within  weeks or five half-lives of the drug (whichever is shorter) prior to Cycle , Day